Aldactone

Nephrotic Syndrome, Ascites, Hypokalemia + 14 more

Treatment

18 FDA approvals

20 Active Studies for Aldactone

What is Aldactone

Spironolactone

The Generic name of this drug

Treatment Summary

Spironolactone is a medication used to treat high blood pressure, heart failure, and other conditions caused by too much aldosterone in the body. It works by preventing the body from reabsorbing too much sodium and water, while allowing the body to retain potassium. It was first developed in 1957 and approved by the FDA in 1960. Off-label uses of spironolactone include treating hirsutism, female pattern hair loss, adult acne, and aiding in medical gender transition.

Spironolactone

is the brand name

image of different drug pills on a surface

Aldactone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Spironolactone

Spironolactone

1960

288

Approved as Treatment by the FDA

Spironolactone, also known as Spironolactone, is approved by the FDA for 18 uses such as Swollen feet or ankles and Ascites .

Swollen feet or ankles

Helps manage Edema

Ascites

Helps manage Ascites

Primary Hyperaldosteronism

Helps manage Primary Hyperaldosteronism

Hypokalemia

chronic heart failure with reduced ejection fraction (NYHA Class IV)

Helps manage chronic heart failure with reduced ejection fraction (NYHA Class IV)

Cirrhosis of the Liver

Helps manage Cirrhosis of the Liver

idiopathic hyperaldosteronism

Helps manage idiopathic hyperaldosteronism

Congestive Heart Failure (CHF)

Helps manage Congestive Heart Failure (CHF)

Hypesthesia

Helps manage chronic heart failure with reduced ejection fraction (NYHA Class IV)

Edema

Helps manage Edema

Hypesthesia

Helps manage chronic heart failure with reduced ejection fraction (NYHA Class III)

Cirrhosis

Helps manage Cirrhosis of the Liver

Hyperaldosteronism

Helps manage Primary Hyperaldosteronism

Nephrotic Syndrome

Helps manage Nephrotic Syndrome

Congestive Heart Failure

Helps manage Congestive Heart Failure (CHF)

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Ascites

Helps manage Ascites

Hyperaldosteronism

Helps manage idiopathic hyperaldosteronism

Effectiveness

How Aldactone Affects Patients

Spironolactone was originally studied for the way it helps the body get rid of water without losing too much potassium. It does this by blocking certain receptors in the kidneys that help regulate sodium, water, and potassium levels. It is similar in structure to a hormone called progesterone, and as a result has some of the same effects, such as increased progesterone levels and anti-androgenic effects.

How Aldactone works in the body

Spironolactone works by blocking sodium and potassium channels in the kidneys. This causes more sodium and water to be released from the body, which is how the drug produces its diuretic and anti-hypertension effects. Potassium is the only ion that is not affected, and instead is retained in the body.

When to interrupt dosage

The endorsed dosage of Aldactone is contingent upon the diagnosed condition, such as Hypesthesia, Congestive Heart Failure and Cirrhosis. The measure of dosage fluctuates, depending on the method of administration specified in the accompanying table.

Condition

Dosage

Administration

Nephrotic Syndrome

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Ascites

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hypokalemia

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Acne Vulgaris

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hyperaldosteronism

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hyperaldosteronism

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Swollen feet or ankles

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hypesthesia

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hypesthesia

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Congestive Heart Failure

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hirsutism

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hypertensive disease

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hyperaldosteronism

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Cirrhosis

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Edema

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Hypertension

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

inadequate response to other therapeutic measures

50.0 mg, , 100.0 mg, 25.0 mg, 25.0 mg/mL, 0.02 mg/mg, 0.05 mg/mg

, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral, Suspension - Oral, Suspension, Gel - Topical, Topical, Gel, Tablet, coated - Oral, Tablet, coated

Warnings

Aldactone has six contra-indications. Any of the conditions given in the table below should preclude the utilization of Aldactone.

Aldactone Contraindications

Condition

Risk Level

Notes

Renal Insufficiency

Do Not Combine

Anuria

Do Not Combine

Acute Kidney Injury

Do Not Combine

Hyperkalemia

Do Not Combine

Pulse Frequency

Do Not Combine

Addison Disease

Do Not Combine

There are 20 known major drug interactions with Aldactone.

Common Aldactone Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The metabolism of Amiodarone can be decreased when combined with Spironolactone.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Spironolactone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Spironolactone.

Cyclosporine

Major

The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.

Dabrafenib

Major

The metabolism of Dabrafenib can be decreased when combined with Spironolactone.

Aldactone Toxicity & Overdose Risk

People who overdose on spironolactone may feel drowsy, confused, have a rash, feel sick to their stomach, become dizzy, or have diarrhea. Treatment for overdose includes keeping hydrated and maintaining electrolyte balance and other vital functions. The toxic dose in mice, rats, and rabbits is greater than 1g/kg. Pregnant women should avoid spironolactone, as it has been reported to cause feminization of male fetuses in animal studies. Spironolactone is present in breast milk, but its long-term effects are still unknown. Animal studies have shown that spironol

image of a doctor in a lab doing drug, clinical research

Aldactone Novel Uses: Which Conditions Have a Clinical Trial Featuring Aldactone?

165 active clinical trials are currently underway to evaluate the utility of Aldactone in managing Hypokalemia, Hirsutism and Nephrotic Syndrome.

Condition

Clinical Trials

Trial Phases

Hypesthesia

8 Actively Recruiting

Not Applicable, Phase 1

Cirrhosis

49 Actively Recruiting

Phase 1, Not Applicable, Phase 3, Phase 2, Phase 4

Ascites

2 Actively Recruiting

Not Applicable, Phase 2

Nephrotic Syndrome

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Hypertension

0 Actively Recruiting

Congestive Heart Failure

12 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Hirsutism

0 Actively Recruiting

Hypokalemia

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Hyperaldosteronism

0 Actively Recruiting

inadequate response to other therapeutic measures

0 Actively Recruiting

Hyperaldosteronism

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Swollen feet or ankles

4 Actively Recruiting

Phase 2, Not Applicable, Phase 4

Hypesthesia

5 Actively Recruiting

Not Applicable, Phase 1

Hyperaldosteronism

0 Actively Recruiting

Edema

0 Actively Recruiting

Aldactone Reviews: What are patients saying about Aldactone?

4.7

Patient Review

4/16/2018

Aldactone for High Blood Pressure

I've been taking this medication for six months to help with my high blood pressure. It's been great, but I started noticing some fatty tissue in my chest recently so I went to the doctor. He got an x-ray and diagnosed it as gynecomastia. Other than that, and a little potassium spike, I believe the benefits of this outweigh the harms.

4.3

Patient Review

10/23/2015

Aldactone for High Blood Pressure

I'm currently using this medication to treat my adult acne, under the guidance of a dermatologist. When I started the drug, my skin broke out pretty badly; however, it's since calmed down. I was supposed to take 50mg each day, but find that 25mg does the trick just fine. The only downside is that it makes me really tired, so I have to be careful about taking it at night. Otherwise, no real side effects to speak of other than an upset stomach on occasion.

3.7

Patient Review

11/29/2015

Aldactone for Accumulation of Fluid caused by Cirrhosis of the Liver

I use this medication for adult acne as well as to help manage my borderline blood pressure. However, I would caution anyone taking this drug against consuming ginger before or while driving and/or operating machinery, as it can cause heart palpitations in large doses.

2.3

Patient Review

4/7/2020

Aldactone for Accumulation of Fluid Resulting from Chronic Heart Failure

I'm an 84-year-old woman who had been taking this medication for three years to address heart problems and water retention. However, after about two and a half years, I started growing breasts. Six months ago, they started getting tender, so I notified my cardiologist. He took me off the medication and told me to check my blood pressure for a week before getting back in touch with him. My blood pressure was good, so I stopped taking the medication.

1.7

Patient Review

1/27/2014

Aldactone for Male Pattern of Hair Distribution or Hirsutism in a Woman

1.3

Patient Review

9/21/2016

Aldactone for Accumulation of Fluid Resulting from Chronic Heart Failure

I had a really terrible reaction to this drug. I developed hives, breathing problems, and extreme dehydration. My blood sugar levels were all over the place, and I was in a lot of pain.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about aldactone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Aldactone a steroid?

"Aldactone is not a steroid, but it does have some steroid-like effects on the hormones aldosterone and testosterone. Aldactone belongs to a class of drugs known as diuretics, which are potassium-sparing."

Answered by AI

What is a Aldactone used for?

"High blood pressure is a major problem because it can lead to strokes, heart attacks, and kidney problems. However, by lowering high blood pressure, these risks can be prevented. In addition, high blood pressure can also be treated by removing excess fluid and improving symptoms such as breathing problems."

Answered by AI

What is Aldactone used for and what are the side effects?

"Aldactone is a medication used to treat heart failure, high blood pressure, or low potassium levels in the blood. It can also be used to treat fluid retention in people with congestive heart failure, cirrhosis of the liver, or a kidney disorder called nephrotic syndrome."

Answered by AI

What type of drug is Aldactone?

"Aldactone is a diuretic, meaning it helps your body get rid of water. It also helps your body retain potassium, which can raise the level of potassium in your blood to too high."

Answered by AI

Clinical Trials for Aldactone

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Meal Macronutrients for Blood Fat Levels

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: * A resting metabolic test captures the air they exhale and measures how much energy they use at rest. * A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. * A Fibroscan is a special type of ultrasound of the liver. * A body surface scan uses lasers to measure the total area of the body. * A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Aldactone clinical trials?

We made a collection of clinical trials featuring Aldactone, we think they might fit your search criteria.
Go to Trials
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

AI-Enabled Identification for Fatty Liver Disease

18+
All Sexes
Los Angeles, CA

The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center (+3 Sites)

Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Waitlist Available
Has No Placebo

University of Alabama at Birmingham

Pankaj Arora, MD, FAHA

Have you considered Aldactone clinical trials?

We made a collection of clinical trials featuring Aldactone, we think they might fit your search criteria.
Go to Trials
Image of NewYork-Presbyterian/Weill Cornell Medical Center in New York, United States.

Melatonin for Liver Cirrhosis

18+
All Sexes
New York, NY

The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.

Recruiting
Has No Placebo

NewYork-Presbyterian/Weill Cornell Medical Center

Adam Buckholz, MD MS

Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA

Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.

Waitlist Available
Has No Placebo

Virginia Commonwealth University

Aarti Sarwal

Have you considered Aldactone clinical trials?

We made a collection of clinical trials featuring Aldactone, we think they might fit your search criteria.
Go to Trials